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It is nowadays widely accepted that primary aldosteronism is the most frequent cause 
of endocrine hypertension. Prevalence rates among patients with hypertension are 
6% in the primary care setting and 11% in tertiary care referral centers (1). The 2016 
Endocrine Society Practice Guidelines (2) recommend screening of hypertensive 
subjects with increased pre-test probability which accounts to roughly 50% of all 
hypertensives. Nevertheless, these recommendations stand isolated and are not fully 
reflected by current hypertension guidelines in the US or Europe. More importantly, 
current health care data suggest that little has changed in terms of screening: 
according to a 2015 survey only 1% of hypertensives are screened in Italy and 2% in 
Germany by general practitioners (3). It is in this context in the current issue of the 
journal, that Ohno et al. publish their data from the recently founded Japan Primary 
Aldosteronism Study (4). 
 
Using the large data set of 2582 patients with primary aldosteronism the authors 
analysed clinical and biochemical factors associated with prevalent cardiovascular 
disease. The patients were treated in 15 university hospitals and 14 city hospitals 
between 2006 and 2016. The data were entered into a nation-wide registry and 
analysed retrospectively after rigid chart review. Primary aldosteronism was 
diagnosed following strict diagnostic criteria including confirmatory testing and ACTH 
stimulated adrenal vein sampling. Successful cannulation of both adrenal veins was 
mandatory for inclusion, using stringent criteria: a selectivity index >5 (corresponding 
to the ratio of the cortisol concentration in the adrenal vein to that in the inferior vena 
cava) defined technical success of the procedure, whereas a lateralization index of 
>4 (aldosterone to cortisol ratio of the dominant adrenal side divided by the non-
dominant side) indicated unilateral aldosteronism.  Data of the patient cohort were 
compared with two hypertensive control cohorts: a smaller cohort from the Kyoto 
Medical Center comprising 236 patients using sex, age and systolic blood pressure 
as matching variables, and 1263 similarly matched hypertensive subjects of the 
population-based Nagahama Study. Because of the large number of patients and the 
careful matching the Ohno study has an unprecedented power. It is its first (“the 
bad”) finding that Japanese patients with primary aldosteronism have an adverse 
cardiovascular risk profiles, such as higher BMI, more prominent proteinuria and a 
higher diabetes rate. This leads to the second finding: patients with primary 
aldosteronism have strikingly higher rates of cardiovascular disease: The prevalence 
of cardiovascular disease was 11% versus 3.4% in the matched hypertensive group. 
This striking difference results from a 3 to 5 times higher stroke rate in primary 
aldosteronism: 7.2% versus 2.5% in the Kyoto Medical Center controls, 8.4% versus 
1.6% in the population based hypertensive control subjects. Especially the high rate 
of cerebral hemorrhage (2.7%) and subarachnoid hemorrhage (0.5%) are 
bothersome, consequences of long-term uncontrolled hypertension. The third 
relevant point made by this study is related to potential risk factors predisposing to 
cardiovascular disease: In multivariate analysis, a low serum potassium ≤ 3.5 mEq/l 
was associated with an 1.8  fold risk of adverse outcome, as was unilateral 
aldosteronism (odds ratio 1.9) and a baseline plasma aldosterone level of  ≥ 125 
pg/ml (odds ratio 1.9). These data are very consistent: more florid cases of primary 
aldosteronism, i.e. aldosterone producing adenoma, a strong biochemical phenotype 
and accordingly low serum potassium levels, lead to more cardiovascular 
comorbidities. This should make it simple for the clinician: clear-cut cases of primary 
aldosteronism carry the highest risk to develop cardiovascular comorbidities and 
should be picked up as early as possible.  
 
Why, then, is primary aldosteronism still underdiagnosed?  Barriers to appropriate 
screening of high risk populations are manifold. There is no clear lead symptom 
(despite hypokalemia as a late symptom). In the recently published Prevalence and 
Clinical Manifestations of Primary Aldosteronism Primary Care Practice trial in Torino 
(5) only 29% of patients were hypokalemic. Secondly, biochemical screening for 
primary aldosteronism is cumbersome and requires pre-analytical considerations. 
This includes adaptation of hypertensive medication to minimize its influence on the 
aldosterone to renin, adjustment of salt consumption, and correction of hypokalemia, 
if present. Thirdly, subtype determination of primary aldosteronism for identification of 
aldosterone producing adenoma requires a tertiary referral center offering adrenal 
vein sampling. Clearly this remains a major bottle neck in diagnostic work-up since 
few centers are available, and even in so-called expert centers technical success rate 
may be discouragingly low (6).   
 
Recent data suggest that unilateral adrenalectomy in patients age 50 or younger, 
who have aldosterone producing adenoma, is associated with excellent hypertension 
cure rates (7). Also, it is undisputed that case finding and treatment of primary 
aldosteronism is cost effective (8). Moreover, personalized treatment of primary 
aldosteronism by adrenalectomy or mineralocorticoid receptor antagonist reduces left 
ventricular mass hypertrophy and microalbuminuria to levels of optimally treated 
control hypertensives over a time span of >10 years. 
 
In summary, the conclusions taken from the Ohno study are simple: patients with 
primary aldosteronism are at high risk for cardiovascular and cerebrovascular events. 
Patients should be identified early on focusing on high risk populations as defined by 
current guidelines (2), vigorously diagnosed and treated. This strategy will reduce the 
burden of disease and save lives. 
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